Asia Pacific Upstream Bioprocessing Market Forecast to 2030 - Regional Analysis by Product Type, Workflow, Usage Type, and Mode

Asia Pacific Upstream Bioprocessing Market Overview

Asia Pacific Upstream Bioprocessing Market Segmentation

• The Asia Pacific upstream bioprocessing market is segmented based on product type, workflow, usage type, mode, and country. Based on product type, the Asia Pacific upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters services held the largest market share in 2022.
• Based on workflow, the Asia Pacific upstream bioprocessing market is categorized into media preparation, cell culture, and cell separation. The cell separation held the largest market share in 2022.
• Based on usage type, the Asia Pacific upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use held a larger market share in 2022.
• Based on mode, the Asia Pacific upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house held a larger market share in 2022.
• Based on country, the Asia Pacific upstream bioprocessing market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific upstream bioprocessing market share in 2022.
• Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, and Entegris Inc are some of the leading companies operating in the Asia Pacific upstream bioprocessing market.

Market Highlights

• Based on product type, the Asia Pacific upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.3% market share in 2022, amassing US$ 697.06 million. It is projected to garner US$ 1.98 billion by 2030 to expand at 14.0% CAGR during 2022-2030.
• The cell separation segment held 41.3% share of Asia Pacific upstream bioprocessing market in 2022, amassing US$ 816.67 million. It is projected to garner US$ 2.42 billion by 2030 to expand at 14.6% CAGR during 2022-2030.
• The single-use segment held 54.8% share of Asia Pacific upstream bioprocessing market in 2022, amassing US$ 1.08 billion. It is projected to garner US$ 3.16 billion by 2030 to expand at 14.4% CAGR during 2022-2030.
• In terms of mode, the Asia Pacific upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house segment held 57.8% share of Asia Pacific upstream bioprocessing market in 2022, amassing US$ 1.14 billion. It is projected to garner US$ 3.22 billion by 2030 to expand at 13.8% CAGR during 2022-2030.
• This analysis states that China captured 30.0% share of Asia Pacific upstream bioprocessing market in 2022. It was assessed at US$ 592.83 million in 2022 and is likely to hit US$ 1.69 billion by 2030, exhibiting a CAGR of 14.1% during 2022-2030.
• In March 2021, HyPerforma DynaDrive S.U.B. in different volumes, 3,000 L and 5,000 L models. Thermo Fisher Scientific's largest commercially accessible S.U.B., the first-of-its-size 5,000 L S.U.B., allows biopharmaceutical businesses to incorporate single-use technologies into large-scale bioprocesses, such as cGMP manufacture at very high cell density and perfusion cell culture.
• In December 2023, Merck has acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. Merck's upstream therapeutic protein portfolio is boosted by the purchase, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific upstream bioprocessing market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific upstream bioprocessing market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.